Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Chrystyn, G. Safioti, H. Keegstra, G. Gopalan (Huddersfield, United Kingdom; Helsingborg, Sweden; Haarlem, Netherlands; Malvern, United States Of America). LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices. Eur Respir J 2014; 44: Suppl. 58, 4258

Member's Comments

No comment yet.

Related content which might interest you: In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015 Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (FRI). Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016 Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 LATE-BREAKING ABSTRACT: Structured light plethysmography to evaluate the effects of acute bronchodilation during tidal breathing in COPD patients Source: International Congress 2014 – Innovative technology and techniques in respiratory function Year: 2014 Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction. Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging in respiratory disease: novel technologies in 2019 Year: 2019 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD Source: International Congress 2016 – Airway biomarkers Year: 2016